360例原发性胆汁性胆管炎患者进展及预后危险因素分析

万玲玲 ,  王姿淼 ,  梁丽娜 ,  卢书明

大连医科大学学报 ›› 2026, Vol. 48 ›› Issue (3) : 217 -224.

PDF (756KB)
大连医科大学学报 ›› 2026, Vol. 48 ›› Issue (3) : 217 -224. DOI: 10.11724/jdmu.2026.03.04
论著

360例原发性胆汁性胆管炎患者进展及预后危险因素分析

作者信息 +

Analysis of risk factors for progression and prognosis of 360 patients with primary biliary cholangitis

Author information +
文章历史 +
PDF (773K)

摘要

目的 分析原发性胆汁性胆管炎(PBC)患者临床特征,探讨 PBC 进展及预后危险因素,并比较常用预后评分模型的预测能力。方法 收集 2012 年 1 月至 2023 年 6 月 360 例住院 PBC 患者的临床资料,分为早期组(220 例)和终末期组(140 例),比较两组患者临床特征,采用二元 Logistic 回归分析 PBC 患者进展及预后危险因素。应用 MedCalc 软件评估常用预后评分模型的预测能力。结果 终末期组 PBC 患者血清 ALT、GGT、前白蛋白、ALB、LDL-C、HDL-C、TG、Chol、载脂蛋白 A、PTA 及血 HB、WBC、PLT 计数均低于早期组(P<0.05),血清 T-BIL、D-BIL、总胆汁酸、D-Dimer、PT、APTT 水平均高于早期组(P<0.05)。终末期组患者补体 C3 和 C4 水平均低于早期组,而 IgA、IgG 及 IgM 则均高于早期组(P<0.05)。HB、PLT、前白蛋白、ALB、TG、补体 C4 降低和 D-BIL、IgA 升高是 PBC 患者预后的独立危险因素。GLOBE score、ALBI score、MELD score 及 European 和 Newcastle 模型均可用于预测 PBC 患者的预后,ROC 曲线下面积分别为 0.851、0.850、0.811、0.812 和 0.778。结论 HB、PLT、前白蛋白、ALB、TG、补体 C4 降低和 D-BIL、IgA 升高是 PBC 患者进展和预后的危险因素。GLOBE score、ALBI score、MELD score 及 European 和 Newcastle 模型具有较好的预测效能。

Abstract

Objective To analyze the clinical characteristics of patients with primary biliary cholangitis (PBC), investigate the risk factors for PBC progression and prognosis and compare the predictive performance of commonly used prognostic scoring models. Methods Clinical data of 360 PBC patients diagnosed between January 2012 and June 2023 were retrospectively collected. Patients were divided into early-stage and end-stage groups, and the clinical characteristics were compared between the two groups. Binary logistic regression was employed to analyze risk factors for PBC progression and prognosis. The predictive performance of commonly used prognostic scoring models was assessed using MedCalc software. Results Serum levels of ALT, GGT, prealbumin, ALB, LDL-C, HDL-C, TG, Chol, apolipoprotein A, PTA, as well as HB, WBC, and PLT counts were significantly lower in the end-stage group compared to the early-stage group (P<0.05). In contrast, T-BIL, D-BIL, total bile acid, homocysteine proteinase inhibitor C, homocysteine, D-Dimer, PT, and APTT levels in the end-stage group were significantly higher (P<0.05). Additionally, complement C3 and C4 levels were lower in the end-stage group, while the mean values of IgA, IgG, and IgM levels were higher (P<0.05). Reduced levels of HB, PLT, prealbumin, ALB, TG, and complement C4, along with elevated levels of D-BIL and IgA, are independent predictors of prognosis in patients with PBC. The GLOBE score, ALBI score, MELD score, as well as the European and Newcastle models, were all effective in predicting the prognosis of PBC patients, with corresponding areas under the ROC curves of 0.851, 0.850, 0.811, 0.812, and 0.778, respectively. Conclusion Lower levels of HB, PLT, prealbumin, ALB, TG, and complement C4, combined with higher levels of D-BIL and IgA, are associated with increased risk of disease progression and prognosis in patients with PBC. The GLOBE score, ALBI score, MELD score, as well as the European and Newcastle models, show strong predictive accuracy.

关键词

原发性胆汁性胆管炎 / 进展 / 预后 / 危险因素

Key words

primary biliary cholangitis / progression / prognosis / risk factors

引用本文

引用格式 ▾
万玲玲,王姿淼,梁丽娜,卢书明. 360例原发性胆汁性胆管炎患者进展及预后危险因素分析[J]. 大连医科大学学报, 2026, 48(3): 217-224 DOI:10.11724/jdmu.2026.03.04

登录浏览全文

4963

注册一个新账户 忘记密码

参考文献

[1]

Lu M, Zhou YR, Haller IV, et al. Increasing prevalence of primary biliary cholangitis and reduced mortality with treatment[J]. Clin Gastroenterol Hepatol, 2018, 16(8): 1342-1350. e1. DOI: 10.1016/j.cgh.2017.12.033.

[2]

Tan JJ, Chung AH, Loo JH, et al. Global epidemiology of primary biliary cholangitis: an updated systematic review and meta-analysis[J]. Clin Gastroenterol Hepatol, 2026, 24(3): 621-632. DOI: 10.1016/j.cgh.2025.03.025.

[3]

Lammers WJ, Hirschfield GM, Corpechot C, et al. Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy[J]. Gastroenterology, 2015, 149(7): 1804-1812. e4. DOI: 10.1053/j.gastro.2015.07.061.

[4]

Efe C, Taşçilar K, Henriksson I, et al. Validation of risk scoring systems in ursodeoxycholic acid-treated patients with primary biliary cholangitis[J]. Am J Gastroenterol, 2019, 114(7): 1101-1108. DOI: 10.14309/ajg.0000000000000290.

[5]

中华医学会肝病学分会. 原发性胆汁性胆管炎的诊断和治疗指南 (2021)[J]. 临床肝胆病杂志, 2022, 38(1): 35-41. DOI: 10.3969/j.issn.1001-5256.2022.01.007.

[6]

Gatselis NK, Goet JC, Zachou K, et al. Factors associated with progression and outcomes of early stage primary biliary cholangitis[J]. Clin Gastroenterol Hepatol, 2020, 18(3): 684-692.e6. DOI: 10.1016/j.cgh.2019.08.013.

[7]

Bowlus CL, Galambos MR, Aspinall RJ, et al. A phase Ⅱ, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis[J]. J Hepatol, 2022, 77(2): 353-364. DOI: 10.1016/j.jhep.2022.02.033.

[8]

John BV, Aitcheson G, Schwartz KB, et al. Male sex is associated with higher rates of liver-related mortality in primary biliary cholangitis and cirrhosis[J]. Hepatology, 2021, 74(2): 879-891. DOI: 10.1002/hep.31776.

[9]

Cheung AC, Lammers WJ, Murillo Perez CF, et al. Effects of age and sex of response to ursodeoxycholic acid and transplant-free survival in patients with primary biliary cholangitis[J]. Clin Gastroenterol Hepatol, 2019, 17(10): 2076-2084.e2. DOI: 10.1016/j.cgh.2018.12.028.

[10]

Carey EJ, Ali AH, Lindor KD. Primary biliary cirrhosis[J]. Lancet, 2015, 386(10003): 1565-1575. DOI: 10.1016/S0140-6736(15)00154-3.

[11]

Carrion AF, Rosen JD, Levy C. Understanding and treating pruritus in primary biliary cholangitis[J]. Clin Liver Dis, 2018, 22(3): 517-532. DOI: 10.1016/j.cld.2018.03.005.

[12]

Floreani A, Franceschet I, Cazzagon N, et al. Extrahepatic autoimmune conditions associated with primary biliary cirrhosis[J]. Clin Rev Allergy Immunol, 2015, 48(2-3): 192-197. DOI: 10.1007/s12016-014-8427-x.

[13]

Sorokin A, Brown JL, Thompson PD. Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: a systematic review[J]. Atherosclerosis, 2007, 194(2): 293-299. DOI: 10.1016/j.atherosclerosis.2006.11.036.

[14]

Reshetnyak VI, Maev IV. Features of lipid metabolism disorders in primary biliary cholangitis[J]. Biomedicines, 2022, 10(12): 3046. DOI: 10.3390/biomedicines10123046.

[15]

Zheng LH, Tian SY, Yang CM, et al. Hypercholesterolemia is associated with dysregulation of lipid metabolism and poor prognosis in primary biliary cholangitis[J]. Clin Gastroenterol Hepatol, 2024, 22(6): 1265-1274. e19. DOI: 10.1016/j.cgh.2024.01.039.

[16]

Shuai ZW, Wang JJ, Badamagunta M, et al. The fingerprint of antimitochondrial antibodies and the etiology of primary biliary cholangitis[J]. Hepatology, 2017, 65(5): 1670-1682. DOI: 10.1002/hep.29059.

[17]

张玉婷, 李嘉泰, 宋晓静, 等. 不同 IgM 水平的原发性胆汁性胆管炎患者治疗应答及预后特点分析[J]. 胃肠病学和肝病学杂志, 2025, 34(2): 250-253. DOI: 10.3969/j.issn.1006-5709.2025.02.017.

[18]

Jiang P, Feng ZH, Sheng L, et al. Morphological, functional, and tissue characterization of silent myocardial involvement in patients with primary biliary cholangitis[J]. Clin Gastroenterol Hepatol, 2022, 20(5): 1112-1121.e4. DOI: 10.1016/j.cgh.2021.08.035.

[19]

Rashidi-Alavijeh J, Nuruzade N, Frey A, et al. Implications of anaemia and response to anaemia treatment on outcomes in patients with cirrhosis[J]. JHEP Rep, 2023, 5(4): 100688. DOI: 10.1016/j.jhepr.2023.100688.

[20]

Haga Y, Kanda T, Sasaki R, et al. Serum Wisteria Floribunda Agglutinin-Positive Mac-2 Binding Protein Could Not Always Predict Early Cirrhosis in Non-Viral Liver Diseases[J]. Diseases, 2016, 4(4): 38. DOI: 10.3390/diseases4040038.

[21]

Wang H, Xu HQ, Wang XM, et al. Red blood cell distribution width to platelet ratio is related to histologic severity of primary biliary cirrhosis[J]. Medicine, 2016, 95(11): e3114. DOI: 10.1097/MD.0000000000003114.

[22]

Lindor KD, Bowlus CL, Boyer J, et al. Primary biliary cholangitis: 2018 practice guidance from the American association for the study of liver diseases[J]. Hepatology, 2019, 69(1): 394-419. DOI: 10.1002/hep.30145.

[23]

Bressler B. Which patients with primary biliary cirrhosis or primary sclerosing cholangitis should undergo endoscopic screening for oesophageal varices detection[J]. Gut, 2005, 54(3): 407-410. DOI: 10.1136/gut.2004.040832.

[24]

Tababi R, Mrabet S, Akkari I, et al. Prognostic scores in primary biliary cholangitis[J]. Future Sci OA, 2024, 10: FSO975. DOI: 10.2144/fsoa-2023-0203.

[25]

屠军, 李慧瑛, 李峰. Child 和 MELD 动态评分在肝硬化患者预后评估中的临床比较[J]. 胃肠病学和肝病学杂志, 2018, 27(1): 75-78. DOI: 10.3969/j.issn.1006-5709.2018.01.017.

[26]

Chan AWH, Chan RCK, Wong GLH, et al. New simple prognostic score for primary biliary cirrhosis: albumin-bilirubin score[J]. J Gastro And Hepatol, 2015, 30(9): 1391-1396. DOI: 10.1111/jgh.12938.

[27]

Prince M, Chetwynd A, Newman W, et al. Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years[J]. Gastroenterology, 2002, 123(4): 1044-1051. DOI: 10.1053/gast.2002.36027.

[28]

Fujita K, Nomura T, Morishita A, et al. Prediction of transplant-free survival through albumin-bilirubin score in primary biliary cholangitis[J]. J Clin Med, 2019, 8(8): 1258. DOI: 10.3390/jcm8081258.

[29]

Chen QL, Zhong R, Wang Y, et al. The albumin-bilirubin score as a predictor of liver-related mortality in primary biliary cholangitis with compensated cirrhosis[J]. Dig Dis, 2023, 41(6): 946-956. DOI: 10.1159/000531557.

[30]

Ito T, Ishigami M, Morooka H, et al. The albumin-bilirubin score as a predictor of outcomes in Japanese patients with PBC: an analysis using time-dependent ROC[J]. Sci Rep, 2020, 10(1): 17812. DOI: 10.1038/s41598-020-74732-3.

[31]

Ronald J, Wang Q, Choi SS, et al. Albumin-bilirubin grade versus MELD score for predicting survival after transjugular intrahepatic portosystemic shunt (TIPS) creation[J]. Diagn Interv Imaging, 2018, 99(3): 163-168. DOI: 10.1016/j.diii.2017.10.008.

[32]

Marenco-Flores A, Rojas Amaris N, Kahan T, et al. The external validation of GLOBE and UK-PBC risk scores for predicting ursodeoxycholic acid treatment response in a large U. S. cohort of primary biliary cholangitis patients[J]. J Clin Med, 2024, 13(15): 4497. DOI: 10.3390/jcm13154497.

[33]

Sohal A, Kowdley KV. Primary biliary cholangitis: promising emerging innovative therapies and their impact on GLOBE scores[J]. Hepatic Med Evid Res, 2023, 15: 63-77. DOI: 10.2147/hmer.s361077.

[34]

Goet JC, Murillo Perez CF, Harms MH, et al. A comparison of prognostic scores (mayo, UK-PBC, and GLOBE) in primary biliary cholangitis[J]. Am J Gastroenterol, 2021, 116(7): 1514-1522. DOI: 10.14309/ajg.0000000000001285.

[35]

Yang F, Yang Y, Wang Q, et al. The risk predictive values of UK-PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis: the additional effect of anti-gp210[J]. Aliment Pharmacol Ther, 2017, 45(5): 733-743. DOI: 10.1111/apt.13927.

[36]

Ludwig J, Dickson ER, McDonald GS. Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis)[J]. Virchows Arch A Pathol Anat Histol, 1978, 379(2): 103-112. DOI: 10.1007/BF00432479.

[37]

常英昊, 王璐, 袁洲, 等. 连续预后评分系统在中国原发性胆汁性胆管炎不同分期患者中的应用及评价[J]. 国际消化病杂志, 2019, 39(2): 102-110. DOI: 10.3969/j.issn.1673-534X.2019.02.008.

[38]

van Buuren HR, Lammers WJ, Harms MH, et al. Surrogate endpoints for optimal therapeutic response to UDCA in primary biliary cholangitis[J]. Dig Dis, 2015, 33(Suppl.2): 118-124. DOI: 10.1159/000440759.

[39]

Feng J, Xu JM, Fu HY, et al. Prognostic scores in primary biliary cholangitis patients with advanced disease[J]. World J Gastrointest Surg, 2023, 15(8): 1774-1783. DOI: 10.4240/wjgs.v15.i8.1774.

基金资助

辽宁省高校基本科研项目(LJ212510161035)

AI Summary AI Mindmap
PDF (756KB)

0

访问

0

被引

详细

导航
相关文章

AI思维导图

/

〈 〉